Home LiteratureArticle Details
PMID: 24620870 Published · ppublish English Editorial Comment

Idelalisib--a PI3Kδ inhibitor for B-cell cancers.

The New England journal of medicine ·Vol. 370 ·No. 11 ·2014-03-13 ·Pages 1061-2

Fruman DA, Cantley LC

Abstract

暂无摘要

MeSH Terms
Antibodies, Monoclonal, Murine-Derived/therapeutic use Antineoplastic Agents/therapeutic use Antineoplastic Combined Chemotherapy Protocols/therapeutic use Female Humans Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy Lymphoma, Non-Hodgkin/drug therapy Male Phosphoinositide-3 Kinase Inhibitors Purines/therapeutic use Quinazolinones/therapeutic use Rituximab
Chemicals
Antibodies, Monoclonal, Murine-Derived Antineoplastic Agents Phosphoinositide-3 Kinase Inhibitors Purines Quinazolinones Rituximab idelalisib
Authors & Affiliations
2 authors, click to expand affiliations / ORCID
Fruman David A
From the Department of Molecular Biology and Biochemistry and Institute for Immunology, University of California, Irvine (D.A.F.); and Weill Cornell Medical College, New York (L.C.C.).
Cantley Lewis C
References (10)
10 references, click to expand
  1. What a tangled web we weave: emerging resistance mechanisms to inhibition of the phosphoinositide 3-kinase pathway.
    Cancer Discov. 2013 Dec;3(12):1345-54 PMID: 24265156
  2. Agammaglobulinemia and absent B lineage cells in a patient lacking the p85α subunit of PI3K.
    J Exp Med. 2012 Mar 12;209(3):463-70 PMID: 22351933
  3. Impaired B cell development and proliferation in absence of phosphoinositide 3-kinase p85alpha.
    Science. 1999 Jan 15;283(5400):393-7 PMID: 9888855
  4. PI3Ks in lymphocyte signaling and development.
    Curr Top Microbiol Immunol. 2010;346:57-85 PMID: 20563708
  5. Xid-like immunodeficiency in mice with disruption of the p85alpha subunit of phosphoinositide 3-kinase.
    Science. 1999 Jan 15;283(5400):390-2 PMID: 9888854
  6. PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma.
    N Engl J Med. 2014 Mar 13;370(11):1008-18 PMID: 24450858
  7. Impaired B and T cell antigen receptor signaling in p110delta PI 3-kinase mutant mice.
    Science. 2002 Aug 9;297(5583):1031-4 PMID: 12130661
  8. PI3K and cancer: lessons, challenges and opportunities.
    Nat Rev Drug Discov. 2014 Feb;13(2):140-56 PMID: 24481312
  9. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia.
    N Engl J Med. 2014 Mar 13;370(11):997-1007 PMID: 24450857
  10. Molecular pathways: targeting the microenvironment in chronic lymphocytic leukemia--focus on the B-cell receptor.
    Clin Cancer Res. 2014 Feb 1;20(3):548-56 PMID: 24323900
Article Info
Journal
The New England journal of medicine
Abbr.
N Engl J Med
ISSN
1533-4406
DOI
10.1056/NEJMe1400055
Published
2014-03-13
Pages
1061-2
Language
English
Region
United States
NLM ID
0255562
PMCID
PMC4088325
Subset
IM
Grants
NCI NIH HHS · P30 CA062203 · United States
NIGMS NIH HHS · R01 GM041890 · United States
Corrections
CommentOn
PMID: 24450857
CommentOn
PMID: 24450858
External Links
PubMed source DOI: 10.1056/NEJMe1400055 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2